跳至主要内容
临床试验/ACTRN12619001548123
ACTRN12619001548123招募中3 期

Double NAC trial: Investigation of increased N-acetylcysteine dosing in patients treated for paracetamol overdose.

Monash Health0 个研究点目标入组 230 人开始时间: 2019年11月11日最近更新:
适应症

试验速览

阶段
3 期
状态
招募中
发起方
Monash Health
入组人数
230

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional
分配方式
Randomised controlled trial
主要目的
Treatment
盲法
Open (masking not used)

入排标准

年龄范围
o limit 至 o limit(—)
性别
All

入选标准

  • Patients requiring NAC following single acute or staggered overdose with abnormal liver function tests on presentation (ALT>40 U/L), or paracetamol concentration more than double the nomogram treatment line, modified-release paracetamol paracetamol ingestions.

排除标准

  • Exclusion criteria will be patients who are pregnant, intoxicated or sedated patients with co-ingested alcohol or sedating drugs. Single acute overdose patients who are at low risk - normal ALT (<40 IU/L) and paracetamol concentrations less than double the nomogram treatment line will be excluded. Patients with an ALT >40 IU/L on admission and documented preexisting liver disease will be excluded.

研究者

发起方
Monash Health

相似试验